Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.40 |
| ▸ | RXRA | P19793 | 2/20 | 0.38 |
| ▸ | RXRB | P28702 | 2/20 | 0.38 |
| ▸ | RXRG | P48443 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 6/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.36 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 2/20 | 0.35 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.35 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.35 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.35 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.35 |
| ▸ | HTR1D | P28221 | 1/20 | 0.35 |
| ▸ | HTR1B | P28222 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.35 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20811702 | 0.88 | DAO (0.40) | DAORXRARXRBRXRGESR1 | |
| SCHEMBL26939102 | 0.86 | KIF11 (0.45) | DAOESR1ESR2TAS1R3TAS1R1 | |
| SCHEMBL12603811 | 0.85 | DAO (0.51) | DAORXRARXRBRXRGESR1 | |
| SCHEMBL11932057 | 0.82 | ALDH1A1 (0.38) | ESR1ESR2TAS1R3TAS1R1AR | |
| SCHEMBL24196658 | 0.82 | DAO (0.36) | DAORXRARXRBRXRGESR1 | |
| SCHEMBL29307386 | 0.80 | ESR1 (0.47) | ESR1ESR2TAS1R3TAS1R1AR | |
| SCHEMBL24987667 | 0.80 | EPHX2 (0.42) | DAOESR1ESR2EPHX2AR | |
| SCHEMBL19347692 | 0.79 | RAB9A (0.49) | RXRARXRBESR1ESR2EPHX2 | |
| SCHEMBL11932055 | 0.79 | ESR1 (0.38) | ESR1ESR2EPHX2TAS1R3TAS1R1 | |
| SCHEMBL15747030 | 0.77 | DAO (0.36) | DAORXRARXRBRXRGESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019055590-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | AMGEN INC. (US) | 2019-03-21 | — | — | WO | disclosed |
| US-20190077793-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | AMGEN INC. | 2019-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190077793-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, TNNC1 | DAO 3291/4885RXRA 4065/4885RXRB 4087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.